Back to News
Market Impact: 0.18
5 Biotech Stocks Worth Adding to Your Portfolio Now
Source: zacks.com
Healthcare & BiotechCompany FundamentalsAnalyst InsightsCorporate Guidance & Outlook
The article argues that new drug approvals and encouraging pipeline progress should keep momentum in the biotech/genetics space despite an uncertain macro backdrop. It highlights that a strong set of companies/portfolios—HALO, RGEN, IOVA, ARQT, and PGEN—are positioned to benefit from solid pipeline progress in a volatile sector.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
ARQT0.25
HALO0.25
IOVA0.25
PGEN0.25
RGEN0.25
More News
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Bank of America is bullish on these top stocks ahead of earnings
- As companies pour billions into Earth-based AI infrastructure, Google is taking the data center race off-planet
- How U.S. know-how is fracking Australia into a gas boom, from Texas oilmen to Trump’s energy secretary
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Big Tech is betting $700 billion on AI. Healthcare will decide whether the bet pays off
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Financial Research Benchmarks: What the Scores Mean
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper